Transfusion Burden in Allogeneic Hematopoietic Stem Cell Transplantation over Time: Experience from a Single Institution

Introduction: Transfusion plays a main role in supportive treatment for patients who receive an allogeneic hematopoietic stem cell transplantation (HSCT). In this study, we compare the transfusion requirements of patients undergoing different modalities of HSCT according to different time periods. The objective is to assess the evolution of HSCT transfusion requirements over time, from a single institution. Methods: The clinical charts and transfusion records of patients who underwent HSCT of different modalities at La Fe University Hospital during a twelve-year period were reviewed (2009–2020). For analysis, we divided the overall time into three periods: 1 from 2009 to 2012, 2 from 2013 to 2016 and 3 from 2017 to 2020. The study included 855 consecutive adult HSCT: 358 HLA-matched related donors (MRD), 134 HLA-matched unrelated donors (MUD), 223 umbilical cord blood transplantation (UCBT) and 140 haploidentical transplants (Haplo-HSCT). Results: There were no significant differences in RBC and PLT requirements or transfusion independence among the three time periods for MUD and Haplo-HSCT. However, the transfusion burden increased significantly for MRD HSCT during the 2017–2020 period. Conclusion: despite HSCT modalities having evolved and changed over time, overall transfusion requirements have not significantly decreased and continue to be a cornerstone of transplantation-supportive care.

[1]  Yonggoo Kim,et al.  Transfusion support in hematopoietic stem cell transplantation , 2023, Blood research.

[2]  M. Sanz,et al.  IMPACT OF POSTTRANSPLANT CYCLOPHOSPHAMIDE ON TRANSFUSION REQUIREMENTS IN HLA MATCHED SIBLING PERIPHERAL BLOOD STEM CELL TRANSPLANTATION. , 2023, Transplantation and cellular therapy.

[3]  C. Solano,et al.  Post-transplant cyclophosphamide and sirolimus based graft-versus-host disease prophylaxis after allogeneic stem cell transplantation for acute myeloid leukemia , 2022, Bone Marrow Transplantation.

[4]  Andrew D. Johnson,et al.  International Forum on Transfusion Practices in Haematopoietic Stem‐Cell Transplantation: Summary , 2021, Vox sanguinis.

[5]  J. Antin,et al.  GVHD Prophylaxis 2020 , 2021, Frontiers in Immunology.

[6]  C. Karanes,et al.  Red blood cell and platelet transfusion support in the first 30 and 100 days after allogeneic hematopoietic cell transplant , 2020, Transfusion.

[7]  E. Albert,et al.  Uniform graft-versus-host disease prophylaxis with posttransplant cyclophosphamide, sirolimus, and mycophenolate mofetil following hematopoietic stem cell transplantation from haploidentical, matched sibling and unrelated donors , 2020, Bone Marrow Transplantation.

[8]  D. Allan,et al.  Liberal Versus Restrictive Red Blood Cell Transfusion Thresholds in Hematopoietic Cell Transplantation: A Randomized, Open Label, Phase III, Noninferiority Trial. , 2020, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[9]  M. Sanz,et al.  Comparison of transfusion requirements in adult patients undergoing Haploidentical or single‐unit umbilical cord blood stem cell transplantation , 2019, European journal of haematology.

[10]  C. Cohn,et al.  Red blood cell product utilization in patients undergoing allogeneic stem cell transplantation , 2019, Transfusion.

[11]  A. Barrett,et al.  Transfusion support for matched sibling allogeneic hematopoietic stem cell transplantation (1993–2010): factors that predict intensity and time to transfusion independence , 2018, Transfusion.

[12]  J. Seghatchian,et al.  Transfusion challenges in hematology oncology and hematopoietic stem cell transplant - Literature review and local experience. , 2017, Transfusion and apheresis science : official journal of the World Apheresis Association : official journal of the European Society for Haemapheresis.

[13]  M. Sanz,et al.  ABO incompatibility does not influence transfusion requirements in patients undergoing single-unit umbilical cord blood transplantation , 2017, Bone Marrow Transplantation.

[14]  A. Avdić,et al.  Comparing the ratio of mean red blood cell transfusion episode rate of 1 unit versus 2 units in hematopoietic stem cell transplant patients , 2016, Transfusion.

[15]  P. Chevallier,et al.  Longer delay of hematological recovery and increased transfusion needs after haploidentical compared to non-haploidentical stem cell transplantation , 2016, Bone Marrow Transplantation.

[16]  J. Sanz,et al.  Toxicity and efficacy of busulfan and fludarabine myeloablative conditioning for HLA-identical sibling allogeneic hematopoietic cell transplantation in AML and MDS , 2016, Bone Marrow Transplantation.

[17]  D. Weisdorf,et al.  Blood transfusions and pulmonary complications after hematopoietic cell transplantation , 2016, Transfusion.

[18]  D. Purtill,et al.  Red cell and platelet transfusion burden following myeloablative allogeneic haemopoietic stem cell transplantation , 2015, Internal medicine journal.

[19]  M. Sanz,et al.  Effect of CD8⁺ cell content on umbilical cord blood transplantation in adults with hematological malignancies. , 2014, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[20]  Y. Kanda,et al.  Investigation of the freely available easy-to-use software ‘EZR' for medical statistics , 2012, Bone Marrow Transplantation.

[21]  Q. Ran,et al.  Clinical Observation of Factors in the Efficacy of Blood Component Transfusion in Patients following Hematopoietic Stem Cell Transplantation , 2012, PloS one.

[22]  D. Weisdorf,et al.  Platelet and red blood cell utilization and transfusion independence in umbilical cord blood and allogeneic peripheral blood hematopoietic cell transplants. , 2011, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[23]  M. Sorror,et al.  The impact of donor type and ABO incompatibility on transfusion requirements after nonmyeloablative haematopoietic cell transplantation , 2010, British journal of haematology.

[24]  A. Ganser,et al.  TRANSPLANTATION AND CELLULAR ENGINEERING: Prolonged isolated red blood cell transfusion requirement after allogeneic blood stem cell transplantation: identification of patients at risk , 2009, Transfusion.

[25]  J. Gajewski,et al.  A review of transfusion practice before, during, and after hematopoietic progenitor cell transplantation. , 2008, Blood.

[26]  S. Asano,et al.  Impact of ABO incompatibility on engraftment and transfusion requirement after unrelated cord blood transplantation: a single institute experience in Japan , 2007, Bone Marrow Transplantation.

[27]  P. Rebulla,et al.  Prophylactic platelet transfusion for haemorrhage after chemotherapy and stem cell transplantation. , 2004, The Cochrane database of systematic reviews.

[28]  P. Sperryn,et al.  Blood. , 1989, British journal of sports medicine.

[29]  C. Cohn Transfusion support issues in hematopoietic stem cell transplantation. , 2015, Cancer control : journal of the Moffitt Cancer Center.